Research Analysts Issue Forecasts for BMRN FY2026 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Cantor Fitzgerald reduced their FY2026 EPS estimates for shares of BioMarin Pharmaceutical in a research report issued on Tuesday, October 28th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biotechnology company will earn $4.72 per share for the year, down from their prior forecast of $4.81. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

A number of other research analysts also recently weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Wedbush reissued an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday. Stifel Nicolaus reduced their target price on shares of BioMarin Pharmaceutical from $91.00 to $73.00 and set a “buy” rating for the company in a research report on Tuesday. Wolfe Research reaffirmed an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Tuesday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $66.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday. Sixteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $90.70.

BioMarin Pharmaceutical Stock Down 3.0%

BioMarin Pharmaceutical stock opened at $51.86 on Wednesday. BioMarin Pharmaceutical has a twelve month low of $51.56 and a twelve month high of $73.51. The firm has a 50 day moving average price of $55.00 and a 200-day moving average price of $57.17. The company has a market capitalization of $9.96 billion, a P/E ratio of 19.50, a P/E/G ratio of 0.67 and a beta of 0.33. The company has a quick ratio of 3.60, a current ratio of 4.83 and a debt-to-equity ratio of 0.10.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in BMRN. AQR Capital Management LLC raised its position in shares of BioMarin Pharmaceutical by 90.7% during the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock valued at $306,429,000 after buying an additional 2,654,768 shares in the last quarter. Nuveen LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 1st quarter valued at $184,475,000. Norges Bank purchased a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $112,352,000. Viking Global Investors LP raised its position in shares of BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after buying an additional 1,488,552 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of BioMarin Pharmaceutical by 212.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after buying an additional 1,083,512 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.